

# Susan L Slager

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4872426/publications.pdf>

Version: 2024-02-01

430  
papers

19,666  
citations

11608

70  
h-index

14702

127  
g-index

432  
all docs

432  
docs citations

432  
times ranked

24074  
citing authors

#	ARTICLE	IF	CITATIONS
1	Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. <i>Leukemia</i> , 2022, 36, 119-125.	3.3	10
2	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. <i>Blood Advances</i> , 2022, 6, 1350-1360.	2.5	9
3	Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. <i>American Journal of Hematology</i> , 2022, 97, 90-98.	2.0	13
4	Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome. <i>Hematological Oncology</i> , 2022, 40, 302-306.	0.8	2
5	Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. <i>Blood Cancer Journal</i> , 2022, 12, 18.	2.8	9
6	Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis. <i>Leukemia</i> , 2022, , .	3.3	1
7	The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S163-S164.	0.6	0
8	Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method. <i>Blood Advances</i> , 2022, 6, 3746-3750.	2.5	2
9	Inherited genetics of adult diffuse glioma and polygenic risk scores—a review. <i>Neuro-Oncology Practice</i> , 2022, 9, 259-270.	1.0	3
10	Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota. <i>Blood Cancer Journal</i> , 2022, 12, 67.	2.8	13
11	Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6. <i>Blood Cancer Journal</i> , 2022, 12, 60.	2.8	2
12	B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1103-1110.	1.1	4
13	Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2022, 111, 32-40.	0.2	1
14	Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRuCIAL study. <i>Blood Cancer Journal</i> , 2022, 12, 79.	2.8	1
15	B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	2
16	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. <i>Leukemia</i> , 2021, 35, 522-533.	3.3	28
17	Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL). <i>Leukemia</i> , 2021, 35, 239-244.	3.3	21
18	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. <i>Annals of Hematology</i> , 2021, 100, 143-155.	0.8	32

#	ARTICLE	IF	CITATIONS
19	Preneoplastic Alterations Define CLL DNA Methylation and Persist through Disease Progression and Therapy. <i>Blood Cancer Discovery</i> , 2021, 2, 54-69.	2.6	16
20	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. , 2021, 5, 200-217.		0
21	Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2021, 149, 535-545.	2.3	4
22	Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes. <i>Human Molecular Genetics</i> , 2021, 30, 1142-1153.	1.4	2
23	Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 47.	2.8	7
24	Common genetic polymorphisms contribute to the association between chronic lymphocytic leukaemia and non-melanoma skin cancer. <i>International Journal of Epidemiology</i> , 2021, 50, 1325-1334.	0.9	4
25	Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. <i>International Journal of Cancer</i> , 2021, 149, 327-336.	2.3	3
26	The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. <i>Blood</i> , 2021, 138, 149-159.	0.6	20
27	Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. <i>Blood</i> , 2021, 137, 2046-2056.	0.6	16
28	Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia. <i>Scientific Reports</i> , 2021, 11, 8318.	1.6	3
29	The prognostic significance of $\langle \text{scp} \rangle \text{del6q23} \langle / \text{scp} \rangle$ in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E203-E206.	2.0	1
30	Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. <i>American Journal of Hematology</i> , 2021, 96, 979-988.	2.0	5
31	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. <i>Blood Cancer Journal</i> , 2021, 11, 86.	2.8	14
32	Occupational insecticide exposure and risk of non-Hodgkin lymphoma: A pooled case-control study from the InterLymph Consortium. <i>International Journal of Cancer</i> , 2021, 149, 1768-1786.	2.3	13
33	Lack of intrafollicular memory CD4 <sup>+</sup> T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 130.	2.8	27
34	Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. <i>Blood Cancer Journal</i> , 2021, 11, 140.	2.8	6
35	CLL-376: Clinical Characteristics and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL), 80 Years of Age or Older. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S324-S325.	0.2	0
36	Utilization of a Targeted Next Generation Sequencing Assay to Identify Copy Number Alterations in Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis. <i>Blood</i> , 2021, 138, 4677-4677.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Favorable Modulation of Chimeric Antigen Receptor T Cells Safety and Efficacy By the Non-Covalent BTK Inhibitor Vecabrutinib. <i>Blood</i> , 2021, 138, 906-906.	0.6	3
38	Prevalence and Overall Survival of Low Count Monoclonal B-Cell Lymphocytosis (LC-MBL): A Screening Study of 8,297 Individuals from the Mayo Clinic Biobank. <i>Blood</i> , 2021, 138, 2632-2632.	0.6	7
39	Vaccination History and Risk of Lymphoma and Its Major Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, , cebp.0383.2021.	1.1	1
40	TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma. <i>Blood</i> , 2021, 138, 901-901.	0.6	1
41	Optimized Inhibition of GM-CSF in Preclinical Models of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. <i>Blood</i> , 2021, 138, 2777-2777.	0.6	0
42	The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models. <i>Blood</i> , 2021, 138, 2412-2412.	0.6	2
43	Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) after Progression on I Alone (V-na <sup>ve</sup> ) or after Progression on Sequential I and V (Double-Refractory). <i>Blood</i> , 2021, 138, 1560-1560.	0.6	0
44	Relationship and Susceptibility to Serious Infections Among Monoclonal B-Cell Lymphocytosis (MBL), Monoclonal Gammopathy of Undetermined Significance (MGUS), and Clonal Hematopoiesis (CH) Premalignant Conditions. <i>Blood</i> , 2021, 138, 3739-3739.	0.6	0
45	B Cell Receptor Signaling Drives APOBEC3 Expression Via Direct Enhancer Regulation in Chronic Lymphocytic Leukemia B Cells. <i>Blood</i> , 2021, 138, 3313-3313.	0.6	0
46	<i>TP53</i> Aberrations and Outcomes in MBL and Untreated CLL. <i>Blood</i> , 2021, 138, 2618-2618.	0.6	0
47	Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. <i>Haematologica</i> , 2020, 105, 765-773.	1.7	64
48	Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways. <i>Human Molecular Genetics</i> , 2020, 29, 70-79.	1.4	17
49	Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2020, 71, 1221-1228.	2.9	22
50	Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. <i>American Journal of Hematology</i> , 2020, 95, E57-E60.	2.0	9
51	Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. <i>Oncologist</i> , 2020, 25, 974-980.	1.9	15
52	Risk factors for hypogammaglobulinemia in chronic lymphocytic leukemia patients treated with anti-CD20 monoclonal antibody-based therapies. <i>Journal of Hematopathology</i> , 2020, 13, 221-229.	0.2	0
53	Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma among patients with chronic lymphocytic leukemia. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1581-1589.	0.6	4
54	Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci. <i>Human Molecular Genetics</i> , 2020, 29, 2761-2774.	1.4	6

#	ARTICLE	IF	CITATIONS
55	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020, 107, 837-848.	2.6	39
56	Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients. <i>EJHaem</i> , 2020, 1, 537-544.	0.4	2
57	Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 44.	2.3	5
58	The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. <i>Cancer Medicine</i> , 2020, 9, 3390-3399.	1.3	36
59	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. <i>Nature Communications</i> , 2020, 11, 3353.	5.8	75
60	Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance. <i>Blood Advances</i> , 2020, 4, 2789-2797.	2.5	20
61	Infectious mononucleosis, immune genotypes, and non-Hodgkin lymphoma (NHL): an InterLymph Consortium study. <i>Cancer Causes and Control</i> , 2020, 31, 451-462.	0.8	4
62	Genome-wide Association Study Identifies HLA-DPB1 as a Significant Risk Factor for Severe Aplastic Anemia. <i>American Journal of Human Genetics</i> , 2020, 106, 264-271.	2.6	25
63	Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia ( CLL ) and monoclonal Bâ€cell lymphocytosis beyond the CLL international prognostic index. <i>American Journal of Hematology</i> , 2020, 95, 906-917.	2.0	17
64	Lipid Trait Variants and the Risk of Non-Hodgkin Lymphoma Subtypes: A Mendelian Randomization Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1074-1078.	1.1	13
65	Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2020, 61, 2383-2388.	0.6	15
66	Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia. <i>Blood</i> , 2020, 136, 39-40.	0.6	1
67	The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. <i>Haematologica</i> , 2020, 105, 2675-2678.	1.7	17
68	Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes. <i>Blood</i> , 2020, 136, 35-36.	0.6	0
69	Comparison of MGUS Prevalence By Race and Family History Risk Groups Using a High Sensitivity Screening Method (MASS-FIX). <i>Blood</i> , 2020, 136, 40-41.	0.6	1
70	Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older. <i>Blood</i> , 2020, 136, 26-27.	0.6	0
71	Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 10-12.	0.6	0
72	Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models. <i>Blood</i> , 2020, 136, 28-29.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Vesicular Stomatitis Virus (VSV) Engineered to Express CD19 Stimulates Anti-CD19 Chimeric Antigen Receptor Modified T Cells and Promotes Their Anti-Tumor Effects. <i>Blood</i> , 2020, 136, 30-31.	0.6	1
74	Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 12-13.	0.6	0
75	Targeting Aberrant Chromatin in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 1-1.	0.6	0
76	Body Mass Index and Clinical Factors Associated with Monoclonal Gammopathy of Undetermined Significance (MGUS) Progression in Olmsted County, Minnesota. <i>Blood</i> , 2020, 136, 15-16.	0.6	0
77	Distinct Gene Expression Signatures in Patients with Richter's Syndrome and Chronic Lymphocytic Leukemia with Prior Exposure to Ibrutinib. <i>Blood</i> , 2020, 136, 30-31.	0.6	1
78	High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. <i>Blood</i> , 2020, 136, 17-18.	0.6	0
79	Genomic Profiling Reveals Molecular Heterogeneity in Patients with Richter's Syndrome (RS) and Progressive Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 16-17.	0.6	1
80	Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 26-27.	0.6	1
81	Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study. <i>Blood</i> , 2020, 136, 7-8.	0.6	0
82	Immunogenicity of a Recombinant Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 49-50.	0.6	1
83	Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. <i>Blood Cancer Journal</i> , 2019, 9, 59.	2.8	9
84	Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes. <i>Genetic Epidemiology</i> , 2019, 43, 844-863.	0.6	28
85	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 73.	2.8	37
86	Two truncating variants in FANCC and breast cancer risk. <i>Scientific Reports</i> , 2019, 9, 12524.	1.6	5
87	Comparison of tumor staging systems for cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 639-645.	0.6	7
88	Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 186, 820-828.	1.2	12
89	Blood transfusion history and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. <i>Cancer Causes and Control</i> , 2019, 30, 889-900.	0.8	4
90	Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma. <i>Blood</i> , 2019, 133, 2776-2789.	0.6	55

#	ARTICLE	IF	CITATIONS
91	Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2019, 60, 2712-2719.	0.6	42
92	Host genetic variation in tumor necrosis factor and nuclear factor- $\kappa$ B pathways and overall survival in mantle cell lymphoma: A discovery and replication study. <i>American Journal of Hematology</i> , 2019, 94, E153-E155.	2.0	1
93	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. <i>American Journal of Hematology</i> , 2019, 94, 658-666.	2.0	19
94	Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 144-152.	0.8	142
95	Identification of factors associated with duplicate rate in ChIP-seq data. <i>PLoS ONE</i> , 2019, 14, e0214723.	1.1	6
96	CORRÂ® ORS Richard A. Brand Award: Disruption in Peroxisome Proliferator-Activated Receptor- $\beta$ (PPAR $\beta$ ) Increases Osteonecrosis Risk Through Genetic Variance and Pharmacologic Modulation. <i>Clinical Orthopaedics and Related Research</i> , 2019, 477, 1800-1812.	0.7	10
97	<p>Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy</p>. <i>Clinical Epidemiology</i> , 2019, Volume 11, 987-996.	1.5	5
98	Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics. <i>Leukemia</i> , 2019, 33, 499-507.	3.3	9
99	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	2.6	711
100	<i>IGH</i> translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes. <i>American Journal of Hematology</i> , 2019, 94, 338-345.	2.0	19
101	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2019, 9, 1539.	1.3	6
102	A Randomized Phase 2 Study Comparing Acabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2019, 134, 4306-4306.	0.6	3
103	BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression. <i>Blood</i> , 2019, 134, 3050-3050.	0.6	3
104	Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database. <i>Blood</i> , 2019, 134, 1610-1610.	0.6	3
105	Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. <i>Blood</i> , 2019, 134, 121-121.	0.6	7
106	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2019, 134, 69-69.	0.6	9
107	Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis. <i>Blood</i> , 2019, 134, 3022-3022.	0.6	0
108	Association between a Polygenic Risk Score for Multiple Myeloma Risk and Overall Survival. <i>Blood</i> , 2019, 134, 4366-4366.	0.6	0



#	ARTICLE	IF	CITATIONS
109	Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients. <i>Blood</i> , 2019, 134, 5215-5215.	0.6	0
110	Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 919-919.	0.6	0
111	Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. <i>Blood</i> , 2019, 134, 923-923.	0.6	0
112	Germline Variation Predicts Treatment Response in Multiple Myeloma. <i>Blood</i> , 2019, 134, 4397-4397.	0.6	0
113	Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. <i>Blood</i> , 2019, 134, 1480-1480.	0.6	0
114	Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 1604-1604.	0.6	3
115	Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era. <i>Blood</i> , 2019, 134, 422-422.	0.6	0
116	Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL). <i>Blood</i> , 2019, 134, 852-852.	0.6	0
117	The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis. <i>Blood</i> , 2019, 134, 3037-3037.	0.6	0
118	Genome-Wide Association Study Identifies an Immune-Related Etiology for Severe Aplastic Anemia. <i>Blood</i> , 2019, 134, 1224-1224.	0.6	0
119	Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. <i>Haematologica</i> , 2018, 103, e237-e240.	1.7	15
120	Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. <i>Blood</i> , 2018, 131, 2541-2551.	0.6	21
121	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , 2018, 132, 49-58.	0.6	130
122	Germline Lysine-Specific Demethylase 1 ( <i>LSD1/KDM1A</i> ) Mutations Confer Susceptibility to Multiple Myeloma. <i>Cancer Research</i> , 2018, 78, 2747-2759.	0.4	56
123	A genome-wide association study of IgM antibody against phosphorylcholine: shared genetics and phenotypic relationship to chronic lymphocytic leukemia. <i>Human Molecular Genetics</i> , 2018, 27, 1809-1818.	1.4	6
124	A susceptibility locus for classical Hodgkin lymphoma at 8q24 near <i>MYC</i> predicts patient outcome in two independent cohorts. <i>British Journal of Haematology</i> , 2018, 180, 286-290.	1.2	13
125	Comparative analysis of de novo assemblers for variation discovery in personal genomes. <i>Briefings in Bioinformatics</i> , 2018, 19, 893-904.	3.2	14
126	Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. <i>Haematologica</i> , 2018, 103, 297-303.	1.7	17



#	ARTICLE	IF	CITATIONS
127	Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy. <i>Oncotarget</i> , 2018, 9, 37173-37184.	0.8	9
128	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1603-1610.	0.8	93
129	Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2018, 8, 97.	2.8	36
130	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. <i>Nature Communications</i> , 2018, 9, 4182.	5.8	15
131	The association of physical activity before and after lymphoma diagnosis with survival outcomes. <i>American Journal of Hematology</i> , 2018, 93, 1543-1550.	2.0	16
132	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. <i>British Journal of Haematology</i> , 2018, 182, 644-653.	1.2	20
133	History of autoimmune conditions and lymphoma prognosis. <i>Blood Cancer Journal</i> , 2018, 8, 73.	2.8	26
134	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. <i>Cancer Research</i> , 2018, 78, 4086-4096.	0.4	34
135	Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. <i>British Journal of Haematology</i> , 2018, 183, 421-427.	1.2	37
136	The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States. <i>Blood</i> , 2018, 132, 1702-1702.	0.6	6
137	Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL. <i>Blood</i> , 2018, 132, 4204-4204.	0.6	1
138	Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. <i>PLoS Genetics</i> , 2018, 14, e1007111.	1.5	30
139	Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL). <i>Blood</i> , 2018, 132, 3116-3116.	0.6	0
140	Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation. <i>Blood</i> , 2018, 132, 1857-1857.	0.6	0
141	Large-Scale Linkage Analysis of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS) Families. <i>Blood</i> , 2018, 132, 4501-4501.	0.6	0
142	Clinical and Quality of Life Predictors of Failure to Achieve Event Free Survival at 24 Months in Patients Aged 70 Years and Older with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 3579-3579.	0.6	0
143	Association between the Risk of Low/High-Count Monoclonal B-Cell Lymphocytosis (MBL) and the Chronic Lymphocytic Leukemia (CLL) Polygenic Risk Score (PRS). <i>Blood</i> , 2018, 132, 5538-5538.	0.6	0
144	Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era. <i>Blood</i> , 2018, 132, 4140-4140.	0.6	0

#	ARTICLE	IF	CITATIONS
145	<i>FCGR3A</i> / <i>2A</i> polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. <i>Hematological Oncology</i> , 2017, 35, 447-455.	0.8	9
146	<i>BRCA2</i> Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2789-2799.	0.4	75
147	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. <i>Nature Communications</i> , 2017, 8, 14175.	5.8	75
148	Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e22-e25.	1.7	11
149	<i>CD49d</i> associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2017, 178, 99-105.	1.2	23
150	Relationship between comorbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia ( <i>CLL</i> ): a prospective cohort study. <i>British Journal of Haematology</i> , 2017, 178, 394-402.	1.2	66
151	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , 2017, 46, 1753-1754i.	0.9	57
152	Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. <i>American Journal of Hematology</i> , 2017, 92, 1362-1369.	2.0	13
153	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017, 4, e000187.	1.1	15
154	Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2017, 58, 1376-1383.	0.6	33
155	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). <i>Leukemia and Lymphoma</i> , 2017, 58, 1630-1639.	0.6	102
156	Prevalence of Low Count (LC) Monoclonal B Cell Lymphocytosis (MBL) and Serious Infections in a Population-Based Cohort of U.S. Adults Participating in a Large Bio-Repository. <i>Blood</i> , 2017, 130, 831-831.	0.6	3
157	The Level of Physical Activity before and after Lymphoma Diagnosis Impacts Overall and Lymphoma-Specific Survival. <i>Blood</i> , 2017, 130, 914-914.	0.6	2
158	Genome-Wide Epigenetic Studies in Human Disease: A Primer on -Omic Technologies. <i>American Journal of Epidemiology</i> , 2016, 183, kww187.	1.6	23
159	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. <i>PLoS ONE</i> , 2016, 11, e0160316.	1.1	12
160	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	2.0	41
161	Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study. <i>American Journal of Hematology</i> , 2016, 91, 687-691.	2.0	20
162	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	1.5	174

#	ARTICLE	IF	CITATIONS
163	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016, 18, 64.	2.2	31
164	A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1609-1618.	1.1	18
165	An analytical workflow for accurate variant discovery in highly divergent regions. <i>BMC Genomics</i> , 2016, 17, 703.	1.2	22
166	Impact of post-alignment processing in variant discovery from whole exome data. <i>BMC Bioinformatics</i> , 2016, 17, 403.	1.2	28
167	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. <i>American Journal of Human Genetics</i> , 2016, 99, 903-911.	2.6	59
168	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1096-1101.	2.0	180
169	Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016, 91, 776-781.	2.0	14
170	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	5.8	93
171	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	5.8	78
172	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. <i>Nature Communications</i> , 2016, 7, 10933.	5.8	94
173	Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016, 91, 677-680.	2.0	14
174	ChIP-seq in studying epigenetic mechanisms of disease and promoting precision medicine: progresses and future directions. <i>Epigenomics</i> , 2016, 8, 1239-1258.	1.0	22
175	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. <i>Human Molecular Genetics</i> , 2016, 25, 1663-1676.	1.4	52
176	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. <i>Blood</i> , 2016, 128, 1104-1104.	0.6	1
177	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. <i>Blood</i> , 2016, 128, 3034-3034.	0.6	5
178	Role of Lncrnas in Early Stage Immunoglobulin Heavy Chain Variable Region (IGHV) Unmutated CLL Disease Progression. <i>Blood</i> , 2016, 128, 4364-4364.	0.6	1
179	Skin Cancers Among Chronic Lymphocytic Leukemia (CLL) Patients - the Effect of UV Radiation and CLL Clinical Characteristics. <i>Blood</i> , 2016, 128, 4772-4772.	0.6	4
180	Risk of Monoclonal Gammopathy of Undetermined Significance in First-Degree Relatives of Multiple Myeloma Cases By Cytogenetic Subtype. <i>Blood</i> , 2016, 128, 4425-4425.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Sensitivity of Ibrutinib Exposed Chronic Lymphocytic Leukemia B-Cells to Inhibition of Axl Receptor Tyrosine Kinase. <i>Blood</i> , 2016, 128, 2020-2020.	0.6	1
182	Liver Dysfunction in Previously Untreated Chronic Lymphocytic Leukemia: Prevalence and Outcomes in a Large Cohort. <i>Blood</i> , 2016, 128, 5585-5585.	0.6	0
183	The Role of Splenectomy in the Care and Treatment of the CLL Patient. <i>Blood</i> , 2016, 128, 5575-5575.	0.6	0
184	No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era. <i>Blood</i> , 2016, 128, 107-107.	0.6	0
185	Clinically Ascertained Monoclonal B-Cell Lymphocytosis: Risk of Progression to Chronic Lymphocytic Leukemia Requiring Therapy and Outcomes. <i>Blood</i> , 2016, 128, 3228-3228.	0.6	0
186	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 2935-2935.	0.6	0
187	Liver Biopsy in Patients with Chronic Lymphocytic Leukemia: Indications and Pathological Findings. <i>Blood</i> , 2016, 128, 5592-5592.	0.6	1
188	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF- $\kappa$ B positive feedback loop in peripheral T-cell lymphoma. <i>Blood</i> , 2015, 125, 3118-3127.	0.6	68
189	BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. <i>Blood</i> , 2015, 125, 658-667.	0.6	108
190	Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 125, 492-498.	0.6	47
191	Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. <i>Blood</i> , 2015, 125, 992-998.	0.6	47
192	The efficacy of ibrutinib in the treatment of Richter syndrome. <i>Blood</i> , 2015, 125, 1676-1678.	0.6	83
193	Familial predisposition and genetic risk factors for lymphoma. <i>Blood</i> , 2015, 126, 2265-2273.	0.6	122
194	Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. <i>Cancer</i> , 2015, 121, 2883-2891.	2.0	77
195	Tumor Budding in Colorectal Carcinoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1340-1346.	2.1	95
196	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. <i>Nature Communications</i> , 2015, 6, 5751.	5.8	58
197	Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1061-1070.	1.1	8
198	Associations between Environmental Exposures and Incident Colorectal Cancer by ESR2 Protein Expression Level in a Population-Based Cohort of Older Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 713-719.	1.1	10

#	ARTICLE	IF	CITATIONS
199	<sc>H</sc>odgkin transformation of chronic lymphocytic leukemia: <sc>I</sc>ncidence, outcomes, and comparison to <i>de novo</i> <sc>H</sc>odgkin lymphoma. American Journal of Hematology, 2015, 90, 334-338.	2.0	69
200	Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer. Journal of Clinical Oncology, 2015, 33, 304-311.	0.8	521
201	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Human Molecular Genetics, 2015, 24, 2966-2984.	1.4	40
202	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. American Journal of Human Genetics, 2015, 96, 5-20.	2.6	76
203	Associations of Non-Hodgkin Lymphoma (NHL) Risk With Autoimmune Conditions According to Putative NHL Loci. American Journal of Epidemiology, 2015, 181, 406-421.	1.6	54
204	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	9.4	513
205	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nature Communications, 2015, 6, 7539.	5.8	38
206	Impact of Ibrutinib and Idelalisib on the Pharmaceutical Cost of Treating Chronic Lymphocytic Leukemia at the Individual and Societal Levels. Journal of Oncology Practice, 2015, 11, 252-258.	2.5	92
207	Base resolution methylome profiling: considerations in platform selection, data preprocessing and analysis. Epigenomics, 2015, 7, 813-828.	1.0	97
208	Identification of recurrent truncated <i><sc>DDX</sc>3X</i> mutations in chronic lymphocytic leukaemia. British Journal of Haematology, 2015, 169, 445-448.	1.2	54
209	Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. Journal of Clinical Oncology, 2015, 33, 3930-3937.	0.8	24
210	Infectious lymphadenitis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare, but important, complication. Leukemia and Lymphoma, 2015, 56, 311-314.	0.6	15
211	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Human Molecular Genetics, 2015, 24, 285-298.	1.4	38
212	Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL): An Analysis of a Large Cohort of Patients Treated in Routine Clinical Practice. Blood, 2015, 126, 2935-2935.	0.6	18
213	Atrial Fibrillation in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2015, 126, 2950-2950.	0.6	5
214	Pure Red Cell Aplasia (PRCA) in Chronic Lymphocytic Leukemia (CLL): Etiology, Therapy, and Outcomes. Blood, 2015, 126, 4169-4169.	0.6	3
215	Disease Progression and Complications Are the Main Cause of Death in Patients with Chronic Lymphocytic Leukemia (CLL) Independent of Age and Comorbidities at Diagnosis. Blood, 2015, 126, 5265-5265.	0.6	4
216	The Importance of Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice. Blood, 2015, 126, 717-717.	0.6	8

#	ARTICLE	IF	CITATIONS
217	Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 131-131.	0.6	0
218	Correlation Between Peripheral Blood Counts and Extent of Bone Marrow Infiltration in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2926-2926.	0.6	0
219	Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma. <i>Blood</i> , 2015, 126, 1501-1501.	0.6	0
220	Mutations in Driver Genes and Changes in Clonal Dynamics Are Associated with Shorter Time to Treatment in MBL Cases. <i>Blood</i> , 2015, 126, 5264-5264.	0.6	0
221	MicroRNA Related Polymorphisms and Breast Cancer Risk. <i>PLoS ONE</i> , 2014, 9, e109973.	1.1	49
222	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Diffuse Large B-Cell Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 15-25.	0.9	98
223	Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 1-14.	0.9	52
224	Skin Cancer Surveillance and Malignancies of the Skin in a Community-Dwelling Cohort of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia. <i>Journal of Oncology Practice</i> , 2014, 10, e1-e4.	2.5	19
225	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	1.5	47
226	Medical History, Lifestyle, and Occupational Risk Factors for Hairy Cell Leukemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 115-124.	0.9	31
227	Chronic lymphocytic leukemia in young (<math>\leq 55</math> years) patients: a comprehensive analysis of prognostic factors and outcomes. <i>Haematologica</i> , 2014, 99, 140-147.	1.7	60
228	Genetic risk of chronic lymphocytic leukemia: a tale of two cities. <i>Leukemia and Lymphoma</i> , 2014, 55, 735-736.	0.6	2
229	Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2079-2084.	0.6	42
230	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Adult Acute Lymphocytic Leukemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 125-129.	0.9	16
231	Hodgkin Transformation of Chronic Lymphocytic Leukemia (CLL): Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S132-S133.	0.2	0
232	RVboost: RNA-seq variants prioritization using a boosting method. <i>Bioinformatics</i> , 2014, 30, 3414-3416.	1.8	34
233	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Marginal Zone Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 52-65.	0.9	70
234	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 87-97.	0.9	32



#	ARTICLE	IF	CITATIONS
235	Associations between Cigarette Smoking, Hormone Therapy, and Folate Intake with Incident Colorectal Cancer by TP53 Protein Expression Level in a Population-Based Cohort of Older Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 350-355.	1.1	11
236	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. <i>Carcinogenesis</i> , 2014, 35, 1012-1019.	1.3	145
237	Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 639-645.	2.0	26
238	Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 130-144.	0.9	265
239	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 1233-1238.	9.4	147
240	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Sporadic Burkitt Lymphoma/Leukemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 106-114.	0.9	32
241	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. <i>American Journal of Human Genetics</i> , 2014, 95, 462-471.	2.6	96
242	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 41-51.	0.9	82
243	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. <i>Nature Communications</i> , 2014, 5, 4999.	5.8	105
244	PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data. <i>Bioinformatics</i> , 2014, 30, 2678-2680.	1.8	43
245	Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines. <i>Cancer</i> , 2014, 120, 2000-2005.	2.0	33
246	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Mantle Cell Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 76-86.	0.9	31
247	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. <i>Human Molecular Genetics</i> , 2014, 23, 6034-6046.	1.4	12
248	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. <i>Breast Cancer Research</i> , 2014, 16, R51.	2.2	14
249	Event-Free Survival at 12 Months (EFS12) from Diagnosis Is a Robust Endpoint for Disease-Related Survival in Patients with Follicular Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2014, 124, 1664-1664.	0.6	8
250	Quality of Life at Diagnosis Independently Predicts Survival in Patients with Aggressive Lymphoma. <i>Blood</i> , 2014, 124, 205-205.	0.6	2
251	Racial Variations in Disease Characteristics, Presentations, Treatments, and Outcomes in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 1989-1989.	0.6	0
252	Exome Sequencing in Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) Families Identifies Cosegregating Functional Variants. <i>Blood</i> , 2014, 124, 1967-1967.	0.6	0



#	ARTICLE	IF	CITATIONS
253	Validation of Elevated Blood Soluble PD-L1 As an Independent Prognostic Marker in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2014, 124, 2998-2998.	0.6	2
254	Transfusion History and Risk of Non-Hodgkin Lymphoma (NHL): an Interlymph Pooled Analysis. <i>Blood</i> , 2014, 124, 3039-3039.	0.6	1
255	Genomic Diversity of Newly Diagnosed Follicular Lymphoma: a Pilot Investigation. <i>Blood</i> , 2014, 124, 1691-1691.	0.6	0
256	CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1475-1484.	2.0	28
257	Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Journal of Clinical Oncology</i> , 2013, 31, 3272-3278.	0.8	259
258	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. <i>American Journal of Human Genetics</i> , 2013, 93, 1046-1060.	2.6	98
259	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	9.4	493
260	Genetic Susceptibility to Chronic Lymphocytic Leukemia. <i>Seminars in Hematology</i> , 2013, 50, 296-302.	1.8	26
261	Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis. <i>British Journal of Haematology</i> , 2013, 163, 326-333.	1.2	35
262	Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium. <i>Cancer Causes and Control</i> , 2013, 24, 125-134.	0.8	20
263	Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: Results from two independent cohorts. <i>Cytokine</i> , 2013, 64, 523-531.	1.4	16
264	Overall and Cancer-Specific Survival of Patients With Breast, Colon, Kidney, and Lung Cancers With and Without Chronic Lymphocytic Leukemia: A SEER Population-Based Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 930-937.	0.8	56
265	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013, 45, 392-398.	9.4	374
266	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013, 45, 353-361.	9.4	960
267	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2013, 45, 868-876.	9.4	179
268	<i>FCGR2A</i> and <i>FCGR3A</i> polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status. <i>Leukemia and Lymphoma</i> , 2013, 54, 2571-2573.	0.6	7
269	The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 290-297.	0.6	58
270	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	1.5	244

#	ARTICLE	IF	CITATIONS
271	Mapping of the <i>IRF8</i> Gene Identifies a 3'UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 461-466.	1.1	13
272	Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2013, 19, 6812-6819.	3.2	64
273	trans Fatty Acid Intake Is Associated with Increased Risk and n3 Fatty Acid Intake with Reduced Risk of Non-Hodgkin Lymphoma. <i>Journal of Nutrition</i> , 2013, 143, 672-681.	1.3	36
274	Diffuse large B-cell lymphoma (DLBCL) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. <i>British Journal of Haematology</i> , 2013, 162, 774-782.	1.2	187
275	Genetic evidence of PTPN22 effects on chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 237-238.	0.6	10
276	Hodgkin Transformation Of Chronic Lymphocytic Leukemia (CLL): Mayo Clinic Experience. <i>Blood</i> , 2013, 122, 1642-1642.	0.6	5
277	Heritable Predisposition To Richter Syndrome In Patients With Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 2867-2867.	0.6	4
278	IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era. <i>Blood</i> , 2013, 122, 362-362.	0.6	2
279	Hypogammaglobulinemia In Patients With Previously Untreated Chronic Lymphocytic Leukemia: Clinical Correlates and Outcomes. <i>Blood</i> , 2013, 122, 4178-4178.	0.6	2
280	Outcomes Of Chronic Lymphocytic Leukemia Patients With Richter Syndrome. <i>Blood</i> , 2013, 122, 4179-4179.	0.6	4
281	Whole-Exome Analysis Of DLBCL Tumors Reveals a Unique Genetic Signature Associated With Aggressive Disease. <i>Blood</i> , 2013, 122, 499-499.	0.6	2
282	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. <i>Blood</i> , 2013, 122, 76-76.	0.6	1
283	Genomic Landscape and Clonal Heterogeneity Underlying Progression and Relapse In Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, 2855-2855.	0.6	0
284	Comparison Of Single Nucleotide Mutations (SNVs) and Copy Number Variants (CNVs) Detection In Formalin Fixed Paraffin Embedded (FFPE) and Paired Frozen Tumor Tissues Using Target Capture and Sequencing Approach. <i>Blood</i> , 2013, 122, 1784-1784.	0.6	0
285	A Meta-Analysis Of Hodgkin Lymphoma Reveals 19p13.3 (TCF3) As a Novel Susceptibility Loc. <i>Blood</i> , 2013, 122, 626-626.	0.6	0
286	Associations Between Intake of Folate and Related Micronutrients with Molecularly Defined Colorectal Cancer Risks in the Iowa Women's Health Study. <i>Nutrition and Cancer</i> , 2012, 64, 899-910.	0.9	33
287	19p13.1 Is a Triple-Negative-Specific Breast Cancer Susceptibility Locus. <i>Cancer Research</i> , 2012, 72, 1795-1803.	0.4	100
288	Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans. <i>Blood</i> , 2012, 120, 1687-1690.	0.6	16

#	ARTICLE	IF	CITATIONS
289	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3879-3884.	3.3	853
290	LIM domain only 2 protein expression, <i>LMO2</i> germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era. Leukemia and Lymphoma, 2012, 53, 1105-1112.	0.6	5
291	PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium. Blood, 2012, 120, 4645-4648.	0.6	34
292	A Two-Stage Evaluation of Genetic Variation in Immune and Inflammation Genes with Risk of Non-Hodgkin Lymphoma Identifies New Susceptibility Locus in 6p21.3 Region. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1799-1806.	1.1	22
293	Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. Blood, 2012, 120, 843-846.	0.6	76
294	A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32. Blood, 2012, 119, 469-475.	0.6	66
295	Common variants within 6p21.31 locus are associated with chronic lymphocytic leukaemia and, potentially, other non-Hodgkin lymphoma subtypes. British Journal of Haematology, 2012, 159, n/a-n/a.	1.2	13
296	Postmenopausal Hormone Therapy and Colorectal Cancer Risk in Relation to Somatic <i>KRAS</i> Mutation Status among Older Women. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 681-684.	1.1	25
297	Cigarette Smoking and Colorectal Cancer Risk by <i>KRAS</i> Mutation Status Among Older Women. American Journal of Gastroenterology, 2012, 107, 782-789.	0.2	32
298	Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women. Gut, 2012, 61, 1299-1305.	6.1	36
299	The association between early life and adult body mass index and physical activity with risk of non-Hodgkin lymphoma: impact of gender. Annals of Epidemiology, 2012, 22, 855-862.	0.9	19
300	Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: A clinic-based case-control study. Cytokine, 2012, 60, 882-889.	1.4	50
301	A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Human Molecular Genetics, 2012, 21, 5373-5384.	1.4	168
302	A comprehensive study of polymorphisms in the <i>ABCB1</i> , <i>ABCC2</i> , <i>ABCC2</i> , <i>NR112</i> genes and lymphoma risk. International Journal of Cancer, 2012, 131, 803-812.	2.3	35
303	Food frequency questionnaire-based estimates of total antioxidant capacity and risk of non-Hodgkin lymphoma. International Journal of Cancer, 2012, 131, 1158-1168.	2.3	37
304	Elevated pretreatment serum levels of interferon-inducible protein 10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. American Journal of Hematology, 2012, 87, 865-869.	2.0	37
305	Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. American Journal of Hematology, 2012, 87, 880-885.	2.0	36
306	Hematologist/oncologist disease-specific expertise and survival: Lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Cancer, 2012, 118, 1827-1837.	2.0	38

#	ARTICLE	IF	CITATIONS
307	Early life sun exposure, vitamin D-related gene variants, and risk of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2012, 23, 1017-1029.	0.8	34
308	Increased prevalence of light chain monoclonal gammopathy of undetermined significance (<sc>LC</sc>â€‹<sc>MGUS</sc>) in firstâ€‹degree relatives of individuals with multiple myeloma. <i>British Journal of Haematology</i> , 2012, 157, 472-475.	1.2	12
309	Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population. <i>Blood</i> , 2012, 120, 1540-1540.	0.6	2
310	Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era: A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource. <i>Blood</i> , 2012, 120, 1546-1546.	0.6	1
311	EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (âˆ™) Counterparts: Results From University of Iowa/Mayo Clinic SPORE. <i>Blood</i> , 2012, 120, 1604-1604.	0.6	1
312	Very High Risk CLL Characterized by a â€‹Double Hitâ€‹ Clone with Both 11q22 and 17p13 Deletion.. <i>Blood</i> , 2012, 120, 2486-2486.	0.6	0
313	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). <i>Blood</i> , 2012, 120, 684-684.	0.6	0
314	Risk of Cancer in Patients with Clinical Monoclonal B-Cell Lymphocytosis (MBL): A Cohort Study of Newly Diagnosed Patients Compared to Controls.. <i>Blood</i> , 2012, 120, 2893-2893.	0.6	0
315	Clinical Utility of PET/CT Scanning in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 3903-3903.	0.6	0
316	Chronic Lymphocytic Leukemia in Young (â‰¥ 55 years) Patients: A Comprehensive Analysis of Prognostic Factors and Outcomes.. <i>Blood</i> , 2012, 120, 2901-2901.	0.6	0
317	Transformation of Chronic Lymphocytic Leukemia Into Diffuse Large B-Cell Lymphoma (Richter's) Tj ETQq1 1 0.784314 rgBT /Overlock 1	0.6	0
318	Analysis of Stem Cell Transplant Referral in a Cohort of Newly Diagnosed Chronic Lymphocytic Leukemia Patients. <i>Blood</i> , 2012, 120, 4252-4252.	0.6	0
319	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. <i>Blood</i> , 2012, 120, 149-149.	0.6	0
320	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. <i>Blood</i> , 2012, 120, 1563-1563.	0.6	0
321	Host Genetics and Risk of Cardiovascular Disease in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. <i>Blood</i> , 2012, 120, 1573-1573.	0.6	0
322	Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies. <i>Blood</i> , 2012, 120, 3637-3637.	0.6	0
323	CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis.. <i>Blood</i> , 2012, 120, 2702-2702.	0.6	0
324	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptorâ€‹negative breast cancer. <i>Nature Genetics</i> , 2011, 43, 1210-1214.	9.4	279

#	ARTICLE	IF	CITATIONS
325	3.12 The Prevalence of Serious Infections in a Community-Based Cohort of Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) Compared to Controls: Results of a Cohort Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S203-S204.	0.2	0
326	3.13 Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Community-based Cohort Study of Newly Diagnosed Patients Compared to Controls. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S204-S205.	0.2	0
327	Alcohol Intake and Colorectal Cancer Risk by Molecularly Defined Subtypes in a Prospective Study of Older Women. <i>Cancer Prevention Research</i> , 2011, 4, 2035-2043.	0.7	17
328	Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 117, 1492-1498.	0.6	110
329	Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. <i>Blood</i> , 2011, 117, 1911-1916.	0.6	118
330	When the negative is positive. <i>Blood</i> , 2011, 117, 1441-1442.	0.6	2
331	Associations between variants in the cyclooxygenase 2 enzyme gene ( <i>PTGS2</i> ) and development of benign prostate enlargement. <i>BJU International</i> , 2011, 108, 1610-1615.	1.3	5
332	Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2011, 71, 6240-6249.	0.4	109
333	Evaluating the Influence of Quality Control Decisions and Software Algorithms on SNP Calling for the Affymetrix 6.0 SNP Array Platform. <i>Human Heredity</i> , 2011, 71, 221-233.	0.4	5
334	GWAS of Follicular Lymphoma Reveals Allelic Heterogeneity at 6p21.32 and Suggests Shared Genetic Susceptibility with Diffuse Large B-cell Lymphoma. <i>PLoS Genetics</i> , 2011, 7, e1001378.	1.5	93
335	Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Prospective Case-Control Study of Newly Diagnosed Patients. <i>Blood</i> , 2011, 118, 3903-3903.	0.6	0
336	Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients. <i>Blood</i> , 2011, 118, 429-429.	0.6	1
337	Prevalence of MBL Increases Over Time In Relatives of CLL Families. <i>Blood</i> , 2011, 118, 3881-3881.	0.6	0
338	Alemtuzumab Use and Survival After Reduced Intensity Allogeneic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2011, 118, 4152-4152.	0.6	1
339	The Prevalence of Serious Infectious Complications in a Cohort of Non-Referral Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) Compared to Controls: Results of a Cohort Study. <i>Blood</i> , 2011, 118, 4610-4610.	0.6	0
340	Race As a Determinant of Disease Biology and Outcomes in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 1785-1785.	0.6	0
341	Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011, 2, 95-113.	0.4	37
342	Familial chronic lymphocytic leukemia. <i>Current Opinion in Hematology</i> , 2010, 17, 350-355.	1.2	33

#	ARTICLE	IF	CITATIONS
343	Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2010, 116, 4777-4787.	2.0	107
344	A comprehensive evaluation of the prognostic significance of 13q deletions in patients with Bâ€chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2010, 148, 544-550.	1.2	79
345	Common occurrence of monoclonal Bâ€cell lymphocytosis among members of highâ€risk CLL families. <i>British Journal of Haematology</i> , 2010, 151, 152-158.	1.2	61
346	Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. <i>Nature Genetics</i> , 2010, 42, 661-664.	9.4	152
347	Genetic Susceptibility Variants for Chronic Lymphocytic Leukemia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1098-1102.	1.1	31
348	A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. <i>Journal of Experimental Medicine</i> , 2010, 207, 2569-2579.	4.2	96
349	Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2010, 28, 412-417.	0.8	75
350	Germline Variation in Apoptosis Pathway Genes and Risk of Nonâ€Hodgkin's Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2847-2858.	1.1	39
351	Tumor Necrosis Factor (TNF) and Lymphotoxin-Â (LTA) Polymorphisms and Risk of Non-Hodgkin Lymphoma in the InterLymph Consortium. <i>American Journal of Epidemiology</i> , 2010, 171, 267-276.	1.6	128
352	Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4191-4198.	0.8	184
353	Association of Mu-Opioid Receptor Variants and Response to Citalopram Treatment in Major Depressive Disorder. <i>American Journal of Psychiatry</i> , 2010, 167, 565-573.	4.0	58
354	A Genomewide Association Study of Citalopram Response in Major Depressive Disorder. <i>Biological Psychiatry</i> , 2010, 67, 133-138.	0.7	289
355	Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 1233-1240.	0.6	18
356	Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. <i>Leukemia and Lymphoma</i> , 2010, 51, 620-627.	0.6	59
357	Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2010, 116, 996-996.	0.6	2
358	Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients. <i>Blood</i> , 2010, 116, 991-991.	0.6	1
359	Monoclonal and Polyclonal Serum Free Light Chains and Clinical Outcome In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 2409-2409.	0.6	0
360	Survival of Patients with Clinically Identified Monoclonal B-Cell Lymphocytosis (MBL) Relative to the Age and Sex Matched General Population. <i>Blood</i> , 2010, 116, 700-700.	0.6	0



#	ARTICLE	IF	CITATIONS
361	Expression of Interferon Regulatory Factor-4 (IRF4/MUM1) Is Associated with Inferior Overall Survival In Peripheral T-Cell Lymphoma. <i>Blood</i> , 2010, 116, 140-140.	0.6	10
362	A BAFF-R Mutation Associated with Non-Hodgkin Lymphoma Exhibits Altered TRAF Binding and Reveals New Insights Into Proximal BAFF-R Signaling. <i>Blood</i> , 2010, 116, 468-468.	0.6	0
363	Investigation of CLL-Susceptibility Loci with Monoclonal B-Cell Lymphocytosis (MBL) Risk and Confirmation of Recently Reported CLL-Susceptibility Loci. <i>Blood</i> , 2010, 116, 2443-2443.	0.6	0
364	Germline Variation in TNF and NF-Kappa B Pathways and Prognosis In Mantle Cell Lymphoma. <i>Blood</i> , 2010, 116, 4127-4127.	0.6	0
365	Infectious Complications In a Prospective Cohort of Community Based Newly Diagnosed Patients with Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2010, 116, 4610-4610.	0.6	0
366	Functional and Clinical Significance of Variants Localized to 8q24 in Colon Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2492-2500.	1.1	37
367	Brief Report: Natural History of Individuals With Clinically Recognized Monoclonal B-Cell Lymphocytosis Compared With Patients With Rai 0 Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 3959-3963.	0.8	123
368	Genetic Variation in B-Cell-Activating Factor Is Associated with an Increased Risk of Developing B-Cell Non-Hodgkin Lymphoma. <i>Cancer Research</i> , 2009, 69, 4217-4224.	0.4	59
369	Validation of a new prognostic index for patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2009, 115, 363-372.	2.0	72
370	Risk of non-Hodgkin lymphoma in association with germline variation in complement genes. <i>British Journal of Haematology</i> , 2009, 145, 614-623.	1.2	15
371	The physician-patient relationship and quality of life: Lessons from chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2009, 33, 263-270.	0.4	37
372	Familial Chronic Lymphocytic Leukemia: What Does it Mean to Me?. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S194-S197.	1.4	12
373	Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. <i>Leukemia and Lymphoma</i> , 2009, 50, 1261-1268.	0.6	69
374	B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. <i>Blood</i> , 2009, 113, 4188-4196.	0.6	104
375	Monoclonal B-Cell Lymphocytosis Is Commonly Observed Among Unaffected Members of High Risk CLL Families.. <i>Blood</i> , 2009, 114, 1232-1232.	0.6	2
376	Influence of Age at Diagnosis On Utility of Prognostic Testing in Patients with CLL.. <i>Blood</i> , 2009, 114, 2342-2342.	0.6	0
377	Vitamin D Deficiency Is Associated with Inferior Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 1952-1952.	0.6	0
378	Germline Variation in Apoptosis Pathway Genes and Risk of Non-Hodgkin Lymphoma.. <i>Blood</i> , 2009, 114, 3933-3933.	0.6	1



#	ARTICLE	IF	CITATIONS
379	Melanoma and Non-Melanoma Skin Cancer in Patients with Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 1268-1268.	0.6	0
380	Family-Associated Monoclonal B Lymphocytosis Shows Differences From CLL That Suggest An Indolent Biology.. Blood, 2009, 114, 1241-1241.	0.6	0
381	Treatment of Patients with Autoimmune Cytopenia and Progressive CLL Using Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP).. Blood, 2009, 114, 4410-4410.	0.6	0
382	Germline Variation in Complement Genes and Event-Free Survival in Follicular Lymphoma.. Blood, 2009, 114, 440-440.	0.6	4
383	Non-Hodgkin lymphoma and obesity: A pooled analysis from the InterLymph Consortium. International Journal of Cancer, 2008, 122, 2062-2070.	2.3	104
384	The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. British Journal of Haematology, 2008, 141, 615-621.	1.2	101
385	Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2008, 49, 49-56.	0.6	176
386	CD5+ Chronic B-Cell Lymphoproliferative Disorders Could Contain a Novel Disease Entity.. Blood, 2008, 112, 2065-2065.	0.6	1
387	Family-Associated Monoclonal B Lymphocytosis Is Commonly Oligoclonal and Expresses Markers Associated with Adverse Risk in CLL. Blood, 2008, 112, 3144-3144.	0.6	2
388	Genetic Variation in Genes That Regulate T-Cell Differentiation and Function Is Associated with An Increased Risk of Developing B-Cell Non-Hodgkin Lymphoma. Blood, 2008, 112, 3762-3762.	0.6	9
389	Statin Use and Prognosis in Patients with Follicular Lymphoma (FL) and Diffuse Large B Cell Lymphoma (DLBCL). Blood, 2008, 112, 583-583.	0.6	2
390	Pharmacokinetic Genes Do Not Influence Response or Tolerance to Citalopram in the STAR*D Sample. PLoS ONE, 2008, 3, e1872.	1.1	144
391	Treatment Free Survival of Patients with MBL and Early CLL: Follow-up of 405 Patients at Mayo Clinic.. Blood, 2008, 112, 2063-2063.	0.6	0
392	B-Cell Count and Survival: Differentiating Chronic Lymphocytic Leukemia (CLL) from and Monoclonal B-Cell Lymphocytosis (MBL) Based on Clinical Outcome.. Blood, 2008, 112, 2062-2062.	0.6	2
393	Higher Intakes of Vegetables, Vitamin E, Manganese and Zinc Are Associated with a Lower Risk of Non-Hodgkin Lymphoma (NHL): Results from a Case-Control Study. Blood, 2008, 112, 3771-3771.	0.6	0
394	Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10,211 cases and 11,905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood, 2007, 109, 3479-3488.	0.6	159
395	Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood, 2007, 110, 4455-4463.	0.6	144
396	A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood, 2007, 110, 3326-3333.	0.6	79

#	ARTICLE	IF	CITATIONS
397	Analysis of Association Between the Serotonin Transporter and Antidepressant Response in a Large Clinical Sample. <i>Biological Psychiatry</i> , 2007, 61, 734-742.	0.7	148
398	Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. <i>British Journal of Haematology</i> , 2007, 139, 255-264.	1.2	112
399	Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2007, 139, 398-404.	1.2	76
400	Chronic lymphocytic leukaemia genetics overview. <i>British Journal of Haematology</i> , 2007, 139, 630-634.	1.2	36
401	Susceptibility genes and B-chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2007, 139, 762-771.	1.2	26
402	Polymorphisms in the BLYS Gene Are Associated with an Increased Risk of Developing B-Cell Non-Hodgkin Lymphoma.. <i>Blood</i> , 2007, 110, 564-564.	0.6	2
403	Molecular Prognostic Factors and Outcome among a Cohort of Patients with Monoclonal B-Cell Lymphocytosis (MBL).. <i>Blood</i> , 2007, 110, 748-748.	0.6	1
404	The Prognostic Significance of Cytopenia in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL).. <i>Blood</i> , 2007, 110, 746-746.	0.6	0
405	Statin Use and Risk of Non-Hodgkin Lymphoma (NHL): Preliminary Results from the Mayo Clinic Case-Control Study.. <i>Blood</i> , 2007, 110, 2615-2615.	0.6	0
406	The Physician-Patient Relationship Impacts Patient Quality of Life in Chronic Lymphocytic Leukemia: Results of an International Survey of 1482 Patients.. <i>Blood</i> , 2007, 110, 2060-2060.	0.6	0
407	Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project. <i>Prostate</i> , 2006, 66, 173-179.	1.2	42
408	Elevated Serum B-Lymphocyte Stimulator Levels in Patients With Familial Lymphoproliferative Disorders. <i>Journal of Clinical Oncology</i> , 2006, 24, 983-987.	0.8	85
409	Autoimmune Cytopenias in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL): The Clinical Implications of Earlier Diagnosis and Longer Follow-Up.. <i>Blood</i> , 2006, 108, 2789-2789.	0.6	5
410	Prior Treatment Relates More Strongly to Richter's Transformation Than ZAP-70, CD38, IgVH Gene Mutation Status, and Cytogenetic Abnormalities: Findings of an Observational Cohort Study of 962 Patients with CLL.. <i>Blood</i> , 2006, 108, 2777-2777.	0.6	0
411	A Large Scale Evaluation of Genetic Variation in Immune and Inflammation Genes and Risk of Non-Hodgkin Lymphoma.. <i>Blood</i> , 2006, 108, 817-817.	0.6	0
412	Sequence Analysis of the Serotonin Transporter and Associations with Antidepressant Response. <i>Biological Psychiatry</i> , 2005, 58, 374-381.	0.7	203
413	Evidence for Genetic Linkage Between a Polymorphism in the Adenosine 2A Receptor and Panic Disorder. <i>Neuropsychopharmacology</i> , 2004, 29, 558-565.	2.8	144
414	Genetic association studies in Alzheimer's disease research: challenges and opportunities. <i>Statistics in Medicine</i> , 2004, 23, 169-178.	0.8	21

#	ARTICLE	IF	CITATIONS
415	Comparison of Microsatellites Versus Single-Nucleotide Polymorphisms in a Genome Linkage Screen for Prostate Cancer Susceptibility Loci. <i>American Journal of Human Genetics</i> , 2004, 75, 948-965.	2.6	129
416	Familial Chronic Lymphocytic Leukemia (CLL): The Mayo Clinic Experience. <i>Blood</i> , 2004, 104, 1906-1906.	0.6	0
417	Genome-wide linkage analysis of systolic blood pressure: a comparison of two approaches to phenotype definition. <i>BMC Genetics</i> , 2003, 4, S13.	2.7	8
418	Luteinizing hormone $\alpha$ polymorphism and risk of familial and sporadic prostate cancer. <i>Prostate</i> , 2003, 56, 30-36.	1.2	19
419	Genome linkage screen for prostate cancer susceptibility loci: Results from the Mayo Clinic familial prostate cancer study. <i>Prostate</i> , 2003, 57, 335-346.	1.2	48
420	No association of germline alteration of MSR1 with prostate cancer risk. <i>Nature Genetics</i> , 2003, 35, 128-129.	9.4	60
421	Mutations in CHEK2 Associated with Prostate Cancer Risk. <i>American Journal of Human Genetics</i> , 2003, 72, 270-280.	2.6	264
422	Evidence for a susceptibility locus for panic disorder near the catechol-O-methyltransferase gene on chromosome 22. <i>Biological Psychiatry</i> , 2002, 51, 591-601.	0.7	118
423	Analysis of the RNASEL Gene in Familial and Sporadic Prostate Cancer. <i>American Journal of Human Genetics</i> , 2002, 71, 116-123.	2.6	105
424	Evaluation of Candidate Genes in Case-Control Studies: A Statistical Method to Account for Related Subjects. <i>American Journal of Human Genetics</i> , 2001, 68, 1457-1462.	2.6	114
425	Case-Control Studies of Genetic Markers: Power and Sample Size Approximations for Armitage's Test for Trend. <i>Human Heredity</i> , 2001, 52, 149-153.	0.4	154
426	Familial Primary Pulmonary Hypertension (Gene PPH1) Is Caused by Mutations in the Bone Morphogenetic Protein Receptor II Gene. <i>American Journal of Human Genetics</i> , 2000, 67, 737-744.	2.6	1,089
427	Patterns of Dietary Fluoride Supplement Use During Infancy. <i>Journal of Public Health Dentistry</i> , 1998, 58, 228-233.	0.5	63
428	Development of smokeless tobacco-induced oral mucosal lesions. <i>Journal of Oral Pathology and Medicine</i> , 1998, 27, 388-394.	1.4	14
429	Investigating the numerical effects of ascertainment bias in linkage analysis: Development of methods and preliminary results. <i>Genetics</i> , 1997, 14, 1119-1124.		16
430	Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Myeloma Patients?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 0, , .	1.1	2